EFFICACY

In a study of 251 teens (aged 12-18 years) with moderate to severe eczema, 42% of those taking Dupixent achieved a 75% or greater improvement in eczema severity after 16 weeks (as measured by the EASI) and 37% experienced significant reductions in daily itch (4 points or greater on the Pruritus NRS score).

In a study of 367 children (aged 6-11 years) with severe eczema, who were also using topical corticosteroids, 67-69% of those who also took dupilumab achieved a 75% or greater improvement in eczema severity after 16 weeks (as measured by the EASI) and 50-58% experienced significant reductions in daily itch (4 points or greater on the Pruritus NRS score) depending on the dosage of dupilumab.

In a study of 162 children (aged 6 months-5 years) with moderate to severe eczema, 53% of children taking Dupixent and a low-potency topical steroid achieved a 75% or greater improvement in eczema severity after 16 weeks (as measured by the EASI).

SAFETY

The most common side effects across all age groups are: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia). These side effects were experienced by less than 15% of patients who took dupilumab.

A recent study found that some patients may also experience facial redness.

EVIDENCE LEVEL

Dupilumab has been well studied. There are over 1000 published research articles on dupilumab use for eczema.

AVAILABILITY

Approved for eczema in the US, Europe, and Canada for individuals 6 months and older. Approved for individuals ages 12 years and older in Australia.

For help paying for this treatment see: DUPIXENT MyWay patient support program.

EFFICACY

In a phase 3 randomized controlled trial in adults, 56% of patients who used tralokinumab along with topical steroids as needed, had a 75% or greater improvement in eczema severity after 16 weeks (as measured by the EASI).

In one study, after 16 weeks, 20-25% of patients had a significant reduction (4-point or greater) in itch scores (measured by the Pruritus NRS score) depending on the dosage of tralokinumab.

Tralokinumab has also been studied in adolescent patients aged 12-17. Tralokinumab was found to have similar efficacy and safety for adolescents as adults.

SAFETY

In a pooled analysis of 5 trials in 1,605 adults, 15.7% of patients experienced viral upper respiratory tract infections, 5.4% had conjunctivitis or eye irritation/infection, and 3.5% had a reaction at the site of injection. Similar results were seen in the adolescent trial.

EVIDENCE LEVEL

Tralokinumab has been well studied. There are over 100 published research articles on tralokinumab use for eczema.

AVAILABILITY

Tralokinumab is approved in the European Union, UK, and Canada for individuals ages 12 years and older with moderate to severe eczema. It is approved in Japan for individuals ages 15 years and older. It is approved in the US, Saudi Arabia, and Switzerland for adults with moderate to severe eczema.

For help paying for this treatment see: Adbry® Advocate™ patient support program.

EFFICACY

In two studies of 283 and 281 patients (aged 12 years and older) with moderate to severe eczema, 52 to 58% of patients taking lebrikizumab experienced a 75% or greater improvement in their eczema severity after 16 weeks (as measured by the EASI). In addition, 40-46% of patients experienced significant itch reduction (4 points or greater measured by Pruritus NRS score) depending on the dosage of lebrikizumab.

SAFETY

The most common side effects from the two studies included: eczema exacerbation (6.0%-10.3%), herpes virus infection (2.8%-3.2%), and skin infection (1.4%-2.8%).

EVIDENCE LEVEL

Lebrikizumab is a relatively new treatment but several studies have been published on its use for eczema.

AVAILABILITY

It is approved in Europe and the US for individuals 12 years and older. Studies in children are underway and more information on trials in children can be found here.

EFFICACY

In two 16-week studies of 1728 patients (aged 12 years and older) with moderate to severe eczema, 42-44% had a 75% improvement in eczema severity (as measured by the EASI) after 16 weeks and 41-43% of patients experienced significant itch reductions (4 points or greater measured by the Pruritus NRS score), while also using topical steroids or topical calcineurin inhibitors.

SAFETY

In two 16-week studies of 1728 patients (aged 12 years and older), the most common side effects included: skin infections (12-18%), worsening eczema (7-11%), non-skin infections (6-9%), and asthma (2-5%).

EVIDENCE LEVEL

Nemolizumab is a relatively new treatment but several studies have been published on its use for eczema.

AVAILABILITY

It is approved in the US for individuals 12 years and older with moderate to severe eczema. Nemolizumab (Mitchga® Syringes) was approved in Japan in 2022 for individuals 13 years and older.